A new immunoassay that tests for the presence of three biomarkers (nicotinamide N-methyltransferase/NNMT, L-plastin/LCP1, and nonmetastatic cells 1 protein /NM23A) appears to be a valid screening method for the early detection of kidney cancer. John Schieszer has the story in today’s Medical Minute.